TD Cowen Maintains Buy on Exagen, Raises Price Target to $10

Benzinga Newsdesk www.benzinga.com Positive 80.2%

Neg 0% Neu 0% Pos 80.2%

TD Cowen analyst Dan Brennan maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $10.

Comments

No comments yet. Be the first!